Skip to content
Subscriber Only

In Race for Blood Cancer Therapy, a Chinese Biotech Firm Surges 500%

  • GenScript has surged since June report of positive data
  • CEO says go-ahead for human trials likely in second quarter
RF Cancer

Source: Science Photo Library/TEVE GS/Brand X via Getty Images

Updated on

In the global race to use human immune cells to fight cancers, a little-known Chinese firm called GenScript Biotech Corp. is emerging as one of the biggest stock gainers.

Among the first Chinese developers of so-called CAR-T cancer therapies, GenScript’s shares have risen more than sixfold since June, when it reported positive results from early studies in 35 patients with a type of blood cancer.